<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04335578</url>
  </required_header>
  <id_info>
    <org_study_id>CAI001</org_study_id>
    <secondary_id>2017-004807-31</secondary_id>
    <nct_id>NCT04335578</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury</brief_title>
  <official_title>A Multicenter, Randomized, Placebo-Controlled Investigator-Blind, Participant-Blind Study to Evaluate Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma SRL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the study is to investigate the safety and tolerability of repeat dosing&#xD;
      with zampilimab in kidney transplant recipients with deteriorating kidney function associated&#xD;
      with chronic allograft injury (CAI).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2019</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is an Investigator-blind and participant-blind study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>From Day 1 (Baseline) to the end of Safety Follow-up Visit (up to Day 680)</time_frame>
    <description>A treatment-emergent adverse event (TEAE) is defined as any event not present prior to the administration of investigational medicinal product (IMP) or any unresolved event already present before administration of IMP that worsens in intensity following exposure to the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of zampilimab</measure>
    <time_frame>From Day 1 (Baseline) to the end of Safety Follow-up Visit (up to Day 680)</time_frame>
    <description>Serum concentration of the drug zampilimab from Baseline to the end of the last Safety Follow-up Visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine concentration of zampilimab</measure>
    <time_frame>From Day 1 (Baseline) to the end of Safety Follow-up Visit (up to Day 680)</time_frame>
    <description>Urine concentration of the drug zampilimab from Baseline to the end of the last Safety Follow-up Visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Chronic Allograft Injury</condition>
  <arm_group>
    <arm_group_label>Zampilimab Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive zampilimab (UCB7858).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to this arm will receive matching Placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zampilimab</intervention_name>
    <description>Participants will receive zampilimab (UCB7858) at pre-specified time-points.</description>
    <arm_group_label>Zampilimab Cohorts</arm_group_label>
    <other_name>UCB7858</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive matching placebo at pre-specified time-points.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Functioning living or deceased donor allograft &gt;=1 year post-transplantation&#xD;
&#xD;
          -  Baseline (screening) biopsy showing Grade II or III interstitial fibrosis/tubular&#xD;
             atrophy (IF/TA) (&gt;=25% IF/TA)&#xD;
&#xD;
          -  Progressive loss in kidney function observed after the first year post-transplant,&#xD;
             defined as an estimated glomerular filtration rate (eGFR) decline of ≥3 mL/min/year&#xD;
             for at least 24 months prior to screening, with a minimum of 2 documented measurements&#xD;
             per year (minimum of 4 documented measurements in the 24-month period, performed at&#xD;
             least 1 month apart)&#xD;
&#xD;
          -  An eGFR &gt;=30 mL/min/1.73 m^2 for a period of 6 months up to screening&#xD;
&#xD;
          -  Stable standard of care concomitant medication for 3 months prior to screening&#xD;
&#xD;
          -  Participant is male or female, &gt;=18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recipient of multi-organ transplant (with the exception of repeated kidney transplant&#xD;
             recipients, and/or corneal transplant recipients)&#xD;
&#xD;
          -  Screening biopsy shows evidence of significant active antibody-mediated rejection that&#xD;
             may affect the conduct of the study (eg, require change in treatment) according to the&#xD;
             Principal Investigator (PI)&#xD;
&#xD;
          -  Screening biopsy shows evidence of T cell-mediated rejection that may affect the&#xD;
             conduct of the study (eg, require change in treatment) according to the PI&#xD;
&#xD;
          -  Screening biopsy shows evidence of de novo or recurrent glomerular disease that may&#xD;
             affect the conduct of the study (eg, require change in treatment) according to the PI&#xD;
&#xD;
          -  Proteinuria ≥1500 mg/g at screening&#xD;
&#xD;
          -  Participant who has a history of biopsy-proven acute rejection or treatment for&#xD;
             suspected acute rejection within 3 months prior to screening&#xD;
&#xD;
          -  Participant has had major surgery (including joint surgery) within 6 months prior to&#xD;
             screening, or has planned surgery within 6 months after the last dose of&#xD;
             investigational medicinal product (IMP)&#xD;
&#xD;
          -  Participant has a current diagnosis of foot ulcer or diagnosis of chronic diabetic&#xD;
             ulcer or history of delayed wound healing&#xD;
&#xD;
          -  Participant has taken concomitant medication of sirolimus or everolimus within 3&#xD;
             months of screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Principal Investigator</role>
    <affiliation>001 844 599 2273 (UCB)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UCB Cares</last_name>
    <phone>001 844 599 2273</phone>
    <email>UCBCares@ucb.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cai001 401</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Cai001 403</name>
      <address>
        <city>Nedlands</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Cai001 402</name>
      <address>
        <city>Randwick</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Cai001 101</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cai001 201</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Cai001 301</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cai001 302</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cai001 501</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>October 3, 2021</last_update_submitted>
  <last_update_submitted_qc>October 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Allograft Injury</keyword>
  <keyword>UCB7858</keyword>
  <keyword>Kidney transplantation</keyword>
  <keyword>CAI</keyword>
  <keyword>zampilimab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Due to the small sample size in this trial, IPD cannot be adequately anonymized i.e., there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

